The fifth protease inhibitor, Agenerase (amprenavir)

May 1999

The fifth protease inhibitor, Agenerase (amprenavir), will soon hit the market...from Glaxo Wellcome.

It will be used in combo therapy with other HIV antiretrovirals.

The usual adult dose is 1200 mg (8 capsules) BID.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote